GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (STU:CUP) » Definitions » Piotroski F-Score

Chugai Pharmaceutical Co (STU:CUP) Piotroski F-Score : 6 (As of Dec. 15, 2024)


View and export this data going back to . Start your Free Trial

What is Chugai Pharmaceutical Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chugai Pharmaceutical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Chugai Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

STU:CUP' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Chugai Pharmaceutical Co was 8. The lowest was 3. And the median was 6.


Chugai Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Chugai Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Piotroski F-Score Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 5.00 7.00 4.00 7.00

Chugai Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 7.00 6.00 6.00 -

Competitive Comparison of Chugai Pharmaceutical Co's Piotroski F-Score

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Net Income was 491.636 + 580.88 + 456.879 + 658.298 = €2,188 Mil.
Cash Flow from Operations was 198.339 + 791.078 + 619.682 + 415.773 = €2,025 Mil.
Revenue was 1634.479 + 1743.874 + 1455.047 + 1859.124 = €6,693 Mil.
Gross Profit was 1138.52 + 1157.556 + 1007.078 + 1341.601 = €4,645 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Jun24) was
(11959.397 + 11519.748 + 12308.148 + 11653.712 + 12123.98) / 5 = €11912.997 Mil.
Total Assets at the begining of this year (Jun23) was €11,959 Mil.
Long-Term Debt & Capital Lease Obligation was €0 Mil.
Total Current Assets was €8,686 Mil.
Total Current Liabilities was €1,707 Mil.
Net Income was 477.896 + 717.046 + 513.593 + 543.21 = €2,252 Mil.

Revenue was 1588.01 + 3068.16 + 2181.825 + 1746.104 = €8,584 Mil.
Gross Profit was 1100.957 + 1578.434 + 1124.391 + 1147.602 = €4,951 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was
(11479.543 + 11988.935 + 13082.713 + 12381.936 + 11959.397) / 5 = €12178.5048 Mil.
Total Assets at the begining of last year (Jun22) was €11,480 Mil.
Long-Term Debt & Capital Lease Obligation was €0 Mil.
Total Current Assets was €8,311 Mil.
Total Current Liabilities was €1,949 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chugai Pharmaceutical Co's current Net Income (TTM) was 2,188. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Chugai Pharmaceutical Co's current Cash Flow from Operations (TTM) was 2,025. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=2187.693/11959.397
=0.1829267

ROA (Last Year)=Net Income/Total Assets (Jun22)
=2251.745/11479.543
=0.19615284

Chugai Pharmaceutical Co's return on assets of this year was 0.1829267. Chugai Pharmaceutical Co's return on assets of last year was 0.19615284. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Chugai Pharmaceutical Co's current Net Income (TTM) was 2,188. Chugai Pharmaceutical Co's current Cash Flow from Operations (TTM) was 2,025. ==> 2,025 <= 2,188 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=0/11912.997
=0

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=0/12178.5048
=0

Chugai Pharmaceutical Co's gearing of this year was 0. Chugai Pharmaceutical Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun24)=Total Current Assets/Total Current Liabilities
=8686.385/1707.463
=5.08730497

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=8310.905/1948.832
=4.26455692

Chugai Pharmaceutical Co's current ratio of this year was 5.08730497. Chugai Pharmaceutical Co's current ratio of last year was 4.26455692. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Chugai Pharmaceutical Co's number of shares in issue this year was 1679.058. Chugai Pharmaceutical Co's number of shares in issue last year was 1679.058. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4644.755/6692.524
=0.69402142

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4951.384/8584.099
=0.57680882

Chugai Pharmaceutical Co's gross margin of this year was 0.69402142. Chugai Pharmaceutical Co's gross margin of last year was 0.57680882. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=6692.524/11959.397
=0.5596038

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun22)
=8584.099/11479.543
=0.74777358

Chugai Pharmaceutical Co's asset turnover of this year was 0.5596038. Chugai Pharmaceutical Co's asset turnover of last year was 0.74777358. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Chugai Pharmaceutical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Chugai Pharmaceutical Co  (STU:CUP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Chugai Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and covid-19 patients.

Chugai Pharmaceutical Co Headlines

No Headlines